Fundraising Fox
/Companies
Sign in

CytomX Therapeutics

NASDAQ: CTMX

South San Francisco, US · Founded 2010 · 104 employees on LinkedIn · 6 known investors

Find your way into CytomX Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

409 people can intro you to Marcia

Ask Charles (Charlie) Fuchs to introduce you to Marcia P. Belvin

You →Charles · together at CytomX Therapeutics →Marcia

196 people can intro you to Sean

Ask Jamie Chen to introduce you to Sean McCarthy

You →Jamie · together at DNAX Research Institute →Sean

89 people can intro you to Leslie

Ask Sam Okafor to introduce you to Leslie Robbins

You →Sam · together at Coherus Biosciences →Leslie

Sign up to find every way you can get introduced to CytomX Therapeutics

  • Your email: who you already know at CytomX Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the CytomX Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.

BiotechHealthtech

Founders & leadership

SM
Sean McCarthyChief Executive OfficerHe holds a D.Phil. in cancer biology from the University of Oxford, an MBA from UC San Diego's Rady School of Management, and a B.Sc. in biochemistry and pharmacology from King's College London, with over 25 years of experience in biotechnology including prior roles at Millennium Pharmaceuticals and SGX Pharmaceuticals, and as a venture partner at Pappas Ventures.
SASean A. McCarthy
Sean A. McCarthyChief Executive Officer and ChairmanSean McCarthy is Chief Executive Officer and Chairman of CytomX Therapeutics, which he has led since 2011. He holds a D.Phil. in cancer biology from the University of Oxford, an MBA from UC San Diego's Rady School of Management, and a B.Sc. in biochemistry and pharmacology from King's College London, and brings over 25 years of biotechnology industry experience including prior roles at Millennium Pharmaceuticals and SGX Pharmaceuticals, as well as venture investment experience at Pappas Ventures.
MP
Marcia P. BelvinSVP, Chief Scientific OfficerMarcia Belvin is Chief Scientific Officer at CytomX Therapeutics, where she leads research on the company's protease-activated biologics platform. She previously spent over 13 years at Genentech leading preclinical teams in cancer biology programs, and held discovery roles at Exelixis in oncology and inflammation, with a B.A. from Harvard University and Ph.D. from UC Berkeley.
DBDawn Benson
Dawn BensonSVP, Quality and Product ManufacturingSVP, Quality and Product Manufacturing at CytomX
WCWayne Chu
Wayne ChuChief Medical Officer
RLRachael Lester
Rachael LesterSVP, Chief Business OfficerRachael Lester is Senior Vice President and Chief Business Officer at CytomX, a clinical-stage biopharmaceutical company developing Probody cancer therapeutics. She brings over 20 years of experience in healthcare and biopharma, including corporate strategy, M&A, portfolio planning, new product commercialization, and corporate finance.
COChris Ogden
Chris OgdenChief Financial OfficerChief Financial Officer at CytomX
LRLeslie Robbins
Leslie RobbinsSVP, Intellectual PropertyLeslie Robbins is Senior Vice President of Intellectual Property at CytomX, a clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics for cancer. She has worked as corporate and intellectual property counsel in the biotechnology and pharmaceutical industries, serving in both in-house and outside counsel roles.
SRStephanie Robertson
Stephanie RobertsonSVP, Alliances & Program LeadershipSVP, Alliances & Program Leadership at CytomX
DODanielle Olander-Moghadassian
Danielle Olander-MoghadassianConsulting Chief Human Resources OfficerHR and organizational development executive with over 25 years of experience in the life sciences industry. She previously served as Chief Human Resources and Organizational Development Officer at CytomX Therapeutics for nearly 11 years, leading cross-functional initiatives spanning HR, IT, and facilities, and now consults with life sciences companies on people strategy and organizational infrastructure.
LALloyd A. Rowland, Jr.
Lloyd A. Rowland, Jr.Consulting General Counsel
MG
Mamata GokhaleSVP, Regulatory Affairs

Investors · 6

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: the VCSheet dataset · Not right? Tell us

Third Rock VenturesreportedBoston · $100K – $5Mvia Neil Exter · board

How we know: the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

Funding

SEC filings, press & company announcements

$350.5M disclosed across 4 of 5 rounds · 2014–2026

▶$30MraisedAug 2023 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Chris OgdenExecutive Officer
  • Marcia BelvinExecutive Officer
  • James MeyersDirector
  • Alan AshworthDirector
  • Matthew YoungDirector
  • Jeff LandauExecutive Officer
  • Halley GilbertDirector
  • Wayne ChuExecutive Officer
  • Elaine JonesDirector
  • Mani MohindruDirector
  • Sean McCarthyExecutive Officer, Director
  • Lloyd RowlandExecutive Officer
Offering amount
$30M
Amount sold
$30M
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$70MraisedJun 2015 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rachel HumphreyDirector
  • Tim ShannonDirector
  • Frederick W. GluckDirector
  • Hoyoung HuhDirector
  • Elaine V. JonesDirector
  • Neil ExterDirector
  • Sean McCarthyExecutive Officer, Director
Offering amount
$70M
Amount sold
$70M
First sale
Jun 2015
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.5MraisedJan 2015 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tim ShannonDirector
  • Frederick W. GluckDirector
  • Elaine V. JonesDirector
  • Sean McCarthyExecutive Officer, Director
  • Neil ExterDirector
  • Hoyoung HuhDirector
Offering amount
$30M
Amount sold
$16.5M
First sale
Dec 2014
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$419Mvaluation at IPOOct 2015 · $12.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

5 people who came through CytomX Therapeutics went on to found or lead other companies.

Tim ShannonDirectorFounded Quarry TheraKrishna PoluChief Medical OfficerFounded Commit BiologicsJeff LandauChief Business Officer and Head of StrategyFounded Stipple BioRachel HumphreyMember Board of DirectorsFounded NormunityTony W. LiangScientist IFounded PTM Therapeutics, Inc.

Frequently asked questions

What does CytomX Therapeutics do?
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.
Who are CytomX Therapeutics's investors?
CytomX Therapeutics's investors include ATEL Ventures, Canaan Partners, Longitude Capital, Pfizer Venture Investments, OrbiMed, Third Rock Ventures.
How much funding has CytomX Therapeutics raised?
CytomX Therapeutics has disclosed $350.5M raised across 4 of its 5 known rounds.
Where is CytomX Therapeutics headquartered?
CytomX Therapeutics is headquartered in South San Francisco, US.